Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial

Research output: Contribution to journalLetter

Authors

External Institution(s)

  • Harvard University
  • Universidade de Brasília
  • University of Utah
  • University of Minnesota Twin Cities
  • University of Michigan, Ann Arbor

Details

Original languageEnglish (US)
Pages (from-to)557-559
Number of pages3
JournalEuropean Journal of Heart Failure
Volume22
Issue number3
StatusPublished - Mar 1 2020
Peer-reviewedYes

Citation formats

APA

Harvard

Ramalho, SHR, Claggett, BL, Sweitzer, NK, Fang, JC, Shah, SJ, Anand, IS, Pitt, B, Lewis, EF, Pfeffer, MA, Solomon, SD & Shah, AM 2020, 'Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial', European Journal of Heart Failure, vol. 22, no. 3, pp. 557-559. https://doi.org/10.1002/ejhf.1593